Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 77Prostatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 50Breast Neoplasms 49Esophageal Neoplasms 47Rectal Neoplasms 41Lung Neoplasms 40Squamous Cell Carcinoma of Head and Neck 32Gliosarcoma 31Head and Neck Neoplasms 30Brain Neoplasms 30Pancreatic Neoplasms 29Uterine Cervical Neoplasms 27Neoplasm Metastasis 23Glioma 23Neoplasms 22Oropharyngeal Neoplasms 20Sarcoma 19Esophageal Squamous Cell Carcinoma 19Melanoma 18Astrocytoma 17Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11Burkitt Lymphoma 10

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Urothelial Carcinoma × Radiation × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡